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Introduction: Placental glutamine synthesis has been demonstrated in animals and is thought to increase
the availability of this metabolically important amino acid to the fetus. Glutamine is of fundamental
importance for cellular replication, cellular function and inter-organ nitrogen transfer. The objective of
this study was to investigate the role of glutamate/glutamine metabolism by the isolated perfused hu-
man placenta in the provision of glutamine to the fetus.
Methods: Glutamate metabolism was investigated in the isolated dually perfused human placental
cotyledon. Ue13C-glutamate was used to investigate the movement of carbon and 15N-leucine to study
movement of amino-nitrogen. Labelled amino acids were perfused via maternal or fetal arteries at
deﬁned ﬂow rates. The enrichment and concentration of amino acids in the maternal and fetal veins
were measured following 5 h of perfusion.
Results: Glutamate taken up from the maternal and fetal circulations was primarily converted into
glutamine the majority of which was released into the maternal circulation. The glutamine transporter
SNAT5 was localised to the maternal-facing membrane of the syncytiotrophoblast. Enrichment of 13C or
15N glutamine in placental tissue was lower than in either the maternal or fetal circulation, suggesting
metabolic compartmentalisation within the syncytiotrophoblast.
Discussion: Placental glutamine synthesis may help ensure the placenta’s ability to supply this amino
acid to the fetus does not become limiting to fetal growth. Glutamine synthesis may also inﬂuence
placental transport of other amino acids, metabolism, nitrogen ﬂux and cellular regulation.
Conclusions: Placental glutamine synthesis may therefore be a central mechanism in ensuring that the
human fetus receives adequate nutrition and is able to maintain growth.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license .1. Introduction
Glutamine and glutamate fulﬁl important metabolic functions
underpinning cellular growth [1,2]. During gestation the growing
fetus will require substantial amounts of these amino acids andntal Sciences, University of
ited Kingdom. Tel.: þ44 (0)
.uk, rml2@soton.ac.uk (R.
r Ltd. Open access under CC BY-NC-NDevidence from animals suggests that placental synthesis of gluta-
mine helps meet fetal demand. However the extent to which
placental glutamate and glutamine metabolism occur in human
placenta and its importance to fetal nutrition is not well
understood.
Studies in the isolated perfused human placenta suggest that
glutamate is converted to another amino acid, probably glutamine,
as it crosses the placenta [3]. This is in keeping with studies in
sheep and other species which show that the placenta synthesises
glutamine from glutamate [4e7]. In sheep, production of glutamine
has been shown to incorporate nitrogen from branched chain
amino acids [8]. Furthermore, in sheep placentalefetal glutaminee
glutamate cycling has been demonstrated suggesting that meta-
bolic interaction between the placenta and other fetal organs is
important in providing the fetus with the nutrients it requires [4]. license.
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the fetus these processes are not well characterised in humans and
as we have demonstrated previously it cannot be assumed that
metabolic processes occurring in other species also occur in
humans [9].
Fetal nutrition is not simply about the amount of nutrients
reaching the fetus, the balance of nutrients is also important. The
relative availability of speciﬁc amino acids may determine the pace
and the nature of fetal growth and development. Thus the relative
composition of amino acids transferred to the fetus may be as
important as their quantity. For instance, high rates of cellular
replication in the rapidly growing fetus create an enhanced de-
mand for nucleotide synthesis and hence the preferential uti-
lisation of glutamine, an absolute requirement for actively dividing
cells [10]. Glutamine is now regarded as a conditionally essential
amino acid and fetal development may be one of those times when
its provision is essential [11].
Placental synthesis may provide an important source of the
conditionally essential amino acid glutamine to the growing fetus.
The aim of this study is therefore to investigate the role of placental
glutamateeglutamine metabolism in the provision of glutamine to
the human fetus.
2. Methods
Human placentas were collected from daytime normal term deliveries from
uncomplicated pregnancies at the Princess Anne Hospital in Southampton. Ethical
approval from the Southampton and Southwest Hampshire Regional Ethics Com-
mittee (REC approval number 308/03/w).
2.1. Perfusions
Placentas were perfused using the methodology of Schneider et al. [12], as
adapted in our laboratory [13,14]. Placentas were collected within 30 min of delivery
and placed on ice for transport to the laboratory where fetal side perfusion was
established within approximately 30 min of collection. The fetal and maternal cir-
culations were perfused with Earle’s bicarbonate buffer ((EBB) (mm): 1.8 CaCl2, 0.4
MgSO4, 116.4 NaCl, 5.4 KCl, 26.2 NaHCO3, 0.9 NaH2PO4, 5.5 glucose, containing 0.1%
bovine serum albumin, and 5000 IU L1 heparin, equilibrated with 95% O2e 5% CO2)
at 6 and 14 ml/min, respectively. Perfusion of the fetal circulation was established
ﬁrst, and, if fetal venous outﬂow was 95% of fetal arterial inﬂow, the maternal
arterial perfusion was established 15 min later. Perfusion was performed for 5 h and
samples were collected from the maternal and fetal veins every hour. At the end of
this perfusion period the maternal and fetal circulations were washed out with EBB
for 15 min, the cotyledon trimmed of non-perfused areas (perfused areas become
white) and the cotyledon frozen for analysis of intracellular amino acids. In 6 pla-
centas where fetal side recovery did not reach 95% maternal and fetal perfusion was
performed for 15e20 min to wash out blood and the tissue was trimmed of non-
perfused areas and frozen for analysis of baseline intracellular amino acid levels.
Four experimental protocols for placental perfusion with stable isotope labelled
amino acids were performed as described in Table 1. 15N-leucine was added to the
maternal circulation as the placenta in vivo takes up leucine from the maternal
circulation and releases leucine into the fetal circulation. 15N-glutamate was added
to bothmaternal and fetal circulations as the placenta takes up glutamate from both
the maternal and fetal circulations.
The Ue13C-glutamate (97e99 atoms percent excess), 15N-leucine (98 atoms
percent excess) and 15N-glutamate (98 atoms percent excess) were all obtained fromTable 1
Experimental parameters and uptake of labelled amino acids.
Protocol Maternal artery ﬂow 14 ml/min Fetal arte
1. Fetal 13C-glutamate Buffer only Ue13C-gl
(zphysio
2. Maternal 15N-leucine 15N-leucine 146 mmol/L
(z2  physiological)
Buffer on
3. Fetal 15N-glutamate Buffer only 15N-gluta
(z2  ph
4. Maternal 15N-glutamate 15N-glutamate 200 mmol/L
(z2  physiological)
Buffer on
Data are mean (SEM).Cambridge Isotope Laboratories, MA, USA. Perfusion of 13C-glutamate was per-
formed at near physiological concentrations while the 15N amino acid perfusions
were at approximately double physiological concentrations. Perfusion with stable
isotope labelled glutamate or leucine was performed for 5 h and samples were
collected from the maternal and fetal veins every hour. At the end of this perfusion
period the maternal and fetal circulations were washed out with EBB for 15 min and
the cotyledon collected for analysis of intracellular amino acids.
2.2. Intracellular amino acids
Frozen cotyledons were pulverised and a sample homogenised in 3 volumes of
ice cold EBB. The homogenate was centrifuged and the supernatant stored at80 C
until analysed by High Pressure Liquid Chromatography (HPLC) and Gas Chroma-
tography Mass Spectrometry (GCMS) as described below.
2.3. Analysis of amino acids by gas chromatography mass spectrometry
Samples were mixed with an equal volume of 1 mol/L acetic acid, applied to a
column containing Dowex 50X8 (Hþ) cation exchanger (Sigma Aldrich Chemical Co.,
Gillingham, UK) and washed with 10 volumes of distilled water. The amino acids
were eluted in 3 mol/L ammonium hydroxide, dried and derivatised at 80 C for 1 h
with a mixture of equal volumes of N-methyl-N-tert-butyldimethylsilyltri-
ﬂuoroacetamide and acetonitrile. GCMS measurements were carried out with an
Agilent 6890/5973 system (Agilent Technologies, Wokingham, UK) on a BPX5
30m  250 mm column in electron impact mode. Isotopomer abundances were
calculated based on the principles described by Wolfe [15].
2.4. Analysis of amino acids by HPLC
Amino acid concentrations were measured by HPLC with ﬂuorescence detection
using nor-valine as an internal standard [16]. Perfusate protein was removed by
centrifugation following addition of an equal volume of 6% sulphosalicylic acid
containing 100 mmol/L nor-valine (Sigma, UK). Immediately following automated
pre-column derivatization of the supernatant with o-phthaldialdehyde/3-mercap-
topropionic acid at pH 9.2 for 100 s at room temperature a 20 mL samplewas injected
into the HPLC system (Gilson HPLC, Anachem, Luton, UK). A binary solvent system
was used to separate the amino acid derivatives on a Supelcosil C18 (25  0.46 cm,
5.0 mm) column (Sigma Aldrich, Gillingham, UK). Solvent A consisted of 100 mmol/L
di-sodium hydrogen phosphate adjusted to pH 6.2 with propionic acid, methanol
and tetrahydrofuran in ratio 460:40:5; Solvent B consisted of water, methanol,
acetonitrile (Fisher Scientiﬁc, Loughborough, UK) in ratio 4:3:3. The eluted com-
ponents were measured by ﬂuorescence (lex ¼ 335 nm, lem ¼ 455 nm). The amino
acid:internal standard (nor-valine) peak area ratio was calculated and samples
quantiﬁed by comparison to the area ratios of known amino standards. The coefﬁ-
cient of variation of the amino acid analysis was 2e5%.
2.5. Analysis of keto acids by HPLC
Concentrations of the keto acids in the maternal and fetal venous outﬂow and
placental tissue homogenates were measured by HPLC using a modiﬁed method of
Pailla [17]. Brieﬂy, 0.5 ml samples and standards were deproteinated by mixing with
an equal volume of 6% w/v sulphosalicylic acid containing 15 mmol/L ketovaleric
acid. An aliquot of the supernatant was mixed with o-phenylenediamine in hy-
drochloric acid, heated at 80 C, cooled, extracted into ethyl acetate and reduced to
dryness under nitrogen. The residue was dissolved in methanol and a 50 mL sample
was analysed by HPLC (Beckman System Gold, BeckmaneCoulter Ltd., High
Wycombe, UK) using a Supelcosil C18 (25  0.46 cm, 5.0 mm) column.
The eluted components were measured by ﬂuorescence (lex ¼ 350 nm,
lem ¼ 410 nm). The response ratio of each keto acid peak was calculated as the area
ratio to the internal standard peak. Concentrations of the individual keto acids were
calculated by comparison to the area ratios of known keto acid standards. The limit
of detection for the keto acids was 0.08 mmol/L for pyruvate, 0.60 mmol/L for a-
ketoisocaproate, 0.03 for a-ketoisovalerate and 0.04 for a-keto-b-methylvalerate.ry ﬂow 6 ml/min Perfused tissue
weight (g)
Labelled amino
acid uptake at
5 h (nmol/min/g)
n
utamate 100 mmol/L
logical)
27.5 (6) 13.3 (2.07) 5
ly 39.3 (8.3) 16.7 (2.1) 5
mate 200 mmol/L
ysiological)
38.8 (10.1) 14.8 (4.5) 4
ly 34.0 (8.3) 17.5 (3.5) 4
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Total RNAwas extracted from placental tissue and reverse transcribed into cDNA
as described previously [14]. Intron spanning primers to human SLC38A3 and
SLC38A5 designed using Primer Express (Applied Bio-systems, California, USA).
SNAT3 (SLC38A3; NM_006841) forward 50-TGCAGACAGAGATGGTGGAG-30 , reverse
50-GTAGCCCAGCTGCTCATAGG-30; SNAT5 (SLC38A5; NM_033518.2) forward 50-
CTGAGCTCCCCCTGGTTATC-30 , reverse 50-CAAAAGCCATAATGGGCACT-30 . PCR was
performed under the following conditions: 94 C for 3 min; 40 cycles at 94 C for
30 s, 60 C for 30 s and 72 C for 30 s; and then 72 C for 7 min (Mastercycler,
Eppendorf AG, Hamburg). PCR products were isolated and sequenced to conﬁrm
their identity (GATC Biotech, Konstanz, Germany).2.7. Western blotting
Microvillous (MVM) and basal membrane (BM) preparations of placental syn-
cytiotrophoblast were isolated as described previously [14,18]. MVM and BM protein
samples (45 mg membrane protein, n ¼ 4) were mixed with loading buffer (RunBlue
LDS Sample Buffer with dithiothreitol at 10 mg/ml; Expedeon Ltd., Harston, Cam-
bridgeshire, UK) and reduced at 70 C for 10 min. Samples were separated by
electrophoresis in 4e12% SDS-PAGE gels and blotted on PVDF-membranes (Expe-
deon). The membranes were blocked overnight at 4 C with 5% Advanced Blocking
Reagent (GE Healthcare, Little Chalfont, UK) in phosphate-buffered salinee0.1%
Tween-20 (PBS-T, pH 7.4). Blots were incubated with primary antibody against
SNAT5 (rabbit, anti-human, ab72717, AbCAM, Cambridge, UK) at a 1:1000 dilution
overnight at 4 C. After washing, blots were incubated for 2 h at room temperature
with 1:100,000 goat HRP-anti-rabbit secondary antibody. Immunoreactive signals
were visualised using enhanced chemiluminescence (SuperSignal West Femto,
Thermo Scientiﬁc, UK). A negative control membrane probed only with secondary
antibody was also used in all cases. Membranes were stripped and incubated with
monoclonal anti-b-actin peroxidise (A3854, Sigma Aldrich, UK) to assess protein
loading.Table 2
Tissue amino acids in perfused and non perfused placentas.
Amino acids Baseline after
15e20 min
perfusion
(mmol/kg tissue)
13C-glu fetal
after 5 h
perfusion
(mmol/kg tissue)
15N-leu maternal
after 5 h
perfusion
(mmol/kg tissue)2.8. Glutamate disposal rate calculations
To derive a value for the rate of glutamate disposal the Mþ5 isotopomer was
used for glutamate and glutamine and the Mþ4 isotopomer was used for aspartate.
The uptake of 13C-glutamate by the placenta was estimated from the fetal venouse
arterial difference. The transfer of 13C-glutamate from the placenta to the maternal
circulationwas calculated as the maternal venousearterial concentration difference
multiplied by the rate of perfusion to derive uptake in nmol/min. The rate of
accumulation of free Mþ5 13C-glutamate or Mþ5 13C-glutamine within the placenta
was estimated as the ﬁnal pool size of the Mþ5 isotopomer for the relevant 13C-
amino acid (nmol/cotyledon) divided by the duration of the experiment in minutes
to give accumulation rate of the Mþ5 isotopomer in nmol/min. Other isotopomers
were not included in these calculations. The placental conversion of glutamate to
glutamine was considered to be at least equal to, or greater, than the measured
release of glutamine into the maternal and fetal circulations plus the accumulation
per minute within tissue. Disposal of 13C-glutamate into the Krebs cycle was
considered to be at least equal to, or greater, than the measured release and accu-
mulation of Mþ4 13C-aspartate: although likely to be an underestimate as we did not
measure other metabolites or CO2. Disposal into the protein and proline pools was
taken to be the balance of glutamate not accounted for by these other routes.n ¼ 6 n ¼ 5 n ¼ 5
Glutamate 1025 (976) 1293 (81)a 731 (36)a,b
Taurine 719 (69) 788 (51) 368 (64)b
Glycine 449 (40) 366 (15) 245 (29)a
Aspartate 348 (38) 496 (97) 230 (21)b
Alanine 296 (42) 200 (11) 134 (8)b
Serine 246 (29) 232 (14) 139 (16)b
Leucine 120 (12) 87 (10) 80 (9)
Lysine 168 (33) 52 (27)a 78 (4)
Threonine 155 (15) 115 (4) 64 (5)a,b
Arginine 104 (11) 108 (7) 59 (8)a,b
Valine 107 (13) 73 (3) 53 (4)a
Glutamine 94 (21) 140 (14) 42 (8)b
Tyrosine 41 (4) 38 (2) 26 (3)
Phenylalanine 51 (5) 45 (5) 24 (2)a,b
a2.9. Analysis of 13C incorporation into lipid pools by LCMS
Samples of placental tissue (100e150 mg) were taken before and after perfusion
(n ¼ 4 each) for lipidomic analysis. Brieﬂy, tissue was homogenised in 1.5 ml of 0.9%
saline on ice and total lipids extracted using dichloromethane and methanol [19].
After drying under nitrogen gas, the lipid residue was dissolved in 1 ml dichlor-
omethane:methanol:water:concentrated ammonia (30:66:3:1 v:v) and introduced
into aWaters XevoTQSmass spectrometer by direct infusion from a Harvard syringe
pump at a ﬂow rate of 8 ml/min. Positive and negative ionisation mass spectra were
collected, followed by diagnostic scans for phosphatidylcholine (PC), phosphati-
dylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), choles-
terol esters (CE) and diacylglycerol (DAG) (1). Peak intensities determined in
MassLynx software were converted to Excel ﬁles and the ratio of M0:Mþ1 peak
intensities for selected species calculated.Isoleucine 49 (6) 41 (5) 19 (2)
Asparagine 39 (4) 53 (4) 21 (2)a,b
Methionine 22 (3) 19 (2) 15 (2)
Histidine 37 (7) 36 (2) 17 (1)b
Data is mean (SEM). Overall analysis by 2 way ANOVA found signiﬁcant effects of
experiment (P < 0.001), amino acid (P < 0.001) and interactions between these
(P < 0.001). Amino acids were compared individually by one way ANOVA followed
by Bonferroni posthoc test.
a Indicates a signiﬁcant difference from initial.
b Indicates that the 15N group is signiﬁcantly different from the 13C group.2.10. Statistics
Enrichment above baseline was determined using a one sample t-test. Speciﬁc
comparisons between placental tissue, maternal vein and fetal veinwere performed
by a paired t test. Analysis of amino acid concentrations in tissue under different
conditions was determined by 2 way ANOVA. Where differences were indicated by
two way ANOVA individual amino acids were analysed by one way ANOVA with
Bonferroni correction. Signiﬁcance was assumed at the 0.05 level. Data are pre-
sented as mean and SEM.3. Results
The weight of the perfused cotyledons in each experimental
group is reported in Table 1. The fetal venous recovery rate in pla-
centas used for the studies was 5.9  0.1 ml/min (98  2% of fetal
inﬂow). Labelled amino acid uptake from the donor circulation
after 5 h of perfusion in the 4 experimental protocols is reported in
Table 1.
3.1. Tissue amino acid concentrations
Concentrations of amino acids were determined in placental
tissue perfused for only 15 min to remove maternal and fetal blood
(baseline tissue concentration) and in the cotyledons following the
5 h perfusions in the Ue13C-glutamate or 15N-leucine experimental
groups (Table 2). Analysis by 2 way ANOVA (group vs amino acid)
indicated that there were signiﬁcant differences in the concentra-
tions of individual amino acids between the experimental groups
(P< 0.001). When individual amino acids levels in the three groups
were compared this indicated that levels of many amino acids in
the 15N-leuicne perfused cotyledons were signiﬁcantly lower than
in baseline or 13C-glutamate perfused cotyledons (Table 2).
3.2. 13C-glutamate experiments
Following infusion of Ue13C-glutamate into the fetal circulation
of the perfused placenta the recovery of the 13C label (other than as
Mþ5 13C-glutamate) as the Mþ5 isotopomer was mainly as 13C-
glutamine which was preferentially released into the maternal
circulation (Fig.1a). As outlined below recovery of 13C label was also
observed in isotopomers of glutamate, aspartate, glutamine and
proline (Fig. 2).
Following infusion of Ue13C-glutamate enrichment of the 13C-
glutamine Mþ5, Mþ4, Mþ3, Mþ2 and Mþ1 isotopomers was
observed in placental tissue, maternal vein and fetal vein (Fig. 2a).
Enrichment of 13C-glutamine in the maternal veinwas signiﬁcantly
(A)
(B)
Fig. 1. Glutamine synthesised within the placenta is primarily released into the
maternal circulation. (A) Following perfusion of the fetal circulation with 13C-gluta-
mate, 13C labelled glutamine, aspartate, and proline (not shown) were released from
placental tissue into fetal vein and maternal vein. (B) Following perfusion of the
maternal circulation with 15N-leucine 15N-labelled glutamine, glutamate, aspartate,
alanine, isoleucine, valine and proline (not shown) were released from placental tissue
into the fetal vein and maternal vein. Data is mean and SEM. N ¼ 5, *P < 0.05 vs
maternal vein.
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different from the fetal vein for Mþ3 isotopomer and lower than in
the fetal vein for Mþ2 andMþ1 isotopomers (Fig. 2a). For the Mþ5,
Mþ4 and Mþ3 isotopomers of 13C-glutamine enrichment in the
maternal and fetal circulations was higher than in placental tissue,
but this was not the case for Mþ2 and Mþ1 isotopomers (Fig. 2a).
Following infusion of Ue13C-glutamate in addition to the re-
covery in the placenta of the Mþ5 glutamate perfused into the
placenta, the Mþ4, Mþ3, Mþ2, and Mþ1 isotopomers of 13C-
glutamate were detected in placental tissue, the fetal vein and the
maternal vein (Fig. 2b). The release of Mþ4 13C-glutamate from the
placenta into the fetal circulationwas signiﬁcantly greater than into
the maternal circulation (P < 0.05, Fig. 1a).Following infusion of Ue13C-glutamate enrichment of the 13C-
aspartate isotopomers Mþ4, Mþ3, Mþ2 and Mþ1 was observed in
placental tissue, maternal vein and fetal vein (Fig. 2c). Enrichment
of the aspartate isotopomers Mþ4 and Mþ2 was signiﬁcantly
greater in the fetal vein compared with placental tissue and
signiﬁcantly greater in placental tissue compared with the
maternal vein (P < 0.05, Fig. 2c). There were no signiﬁcant differ-
ences in the enrichment of Mþ3 and Mþ1 13C-aspartate amongst
the three pools (Fig. 2c). There was signiﬁcantly more Mþ4 13C-
aspartate released into the fetal vein than the maternal vein
(P < 0.05, Fig. 1a).
Following infusion of Ue13C-glutamate enrichment of the 13C-
proline isotopomers Mþ5, Mþ4 was observed in placental tissue,
maternal vein and fetal vein (Fig. 2d). Enrichment of Mþ5 andMþ4
proline was signiﬁcantly greater in the fetal vein than in the
placenta or maternal vein (P < 0.05, Fig. 2d). Enrichment of Mþ3
and Mþ2 13C-proline was only observed in the placenta. Enrich-
ment of Mþ1 13C-proline in fetal vein and in placenta was signiﬁ-
cantly greater than in the maternal vein where there was no
detectable enrichment (Fig. 2d). Proline was not detected by HPLC
and hence the release of 13C-proline into the maternal or fetal cir-
culations was not determined.
Estimates for disposal of 13C-glutamate into different amino acid
pools after 5 h perfusion in a quasi isotopic and metabolic steady
state are presented in Fig. 3.
Following infusion with 13C-glutamate there was no detectable
enrichment in alanine, glycine, valine, leucine, isoleucine, aspara-
gine, serine, threonine, lysine, phenylalanine and tyrosine. The
method did not allow measurement of enrichment in arginine or
cysteine.
3.3. 15N-leucine experiments
Following perfusion of 15N-leucine into thematernal artery, 15N-
labelled amino acids were released into fetal vein as glutamate,
glutamine, aspartate, alanine, leucine and valine (Fig.1b). Following
perfusion of 15N-leucine into the maternal artery labelled amino
acids were recovered from placental tissue and one or both of the
placental circulations: glutamate, glutamine, aspartate, alanine,
isoleucine, valine and proline. There were signiﬁcant differences in
the levels of enrichment of speciﬁc amino acids recovered from the
placenta compared to the maternal and fetal veins (Fig. 2e).
Following perfusion of 15N-leucine into the maternal artery the
greatest recovery of 15N label (other than as 15N-leucine) was as
15N-glutamine in the maternal vein, similar to the results following
infusion with 13C-glutamate into the fetal artery (Fig. 1).
3.4. Branched chain keto-acid and pyruvate concentrations in the
15N-leucine experiments
Following perfusion of 15N-leucine into the maternal artery, the
concentrations of the keto analogues of the branched chain amino
acids as a-keto-isocaproic acid, a-keto-isovaleric acid and a-keto-b-
methylvaleric acid were measured in placental tissue and maternal
vein, however the concentrations in the fetal vein were near the
limit of detection. In placental tissue the concentrations (n ¼ 5,
mean (SEM)) were: a-ketoisovalerate, 790 nmol/L (237); a-ketoi-
socaproate, 149 nmol/L (78) and a-keto-b-methylvalerate,
465 nmol/L (154). From the maternal vein the appearance of
branched chain keto acids was: a-ketoisovalerate 49 nmol/min (4),
a-ketoisocaproate, 234 nmol/min (36) and a-keto-b-methyl-
valerate, 34 nmol/min (10). From the fetal vein (n ¼ 5) the values
were near the limit of detection: a-ketoisovalerate, 1 nmol/min (1);
a-ketoisocaproate, 4 nmol/min (4) and a-keto-b-methylvalerate,
1 nmol/min (1). Release of pyruvate was signiﬁcantly greater into
Fig. 2. Amino acid enrichment and concentrations in the fetal vein and placental tissue following 5 h perfusion of 100 mmol/L 13C-glutamate into the fetal vein of the isolated
perfused placenta (AeD) or 15N-leucine into the maternal arterial circulation (E). (A) Isotopomers of 13C-glutamate appearing in placental tissue, fetal vein and maternal vein
samples. (B) Isotopomers of 13C-glutamine appearing in placental tissue, fetal vein and maternal vein samples. (C) Isotopomers of 13C-aspartate appearing in placental tissue, fetal
vein and maternal vein samples. (D) Isotopomers of 13C-proline appearing in placental tissue, fetal vein and maternal vein samples. (E) Distribution of 15N label following maternal
arterial perfusion of 15N-leucine (N ¼ 5). Data is mean and SEM. N ¼ 5, *P < 0.05 vs placental tissue, qP < 0.05 vs maternal vein.
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(0.12) mmol/min) (P < 0.001).
3.5. 15N-glutamate experiments
Following perfusion of 15N-glutamate into either the fetal artery
(protocol 3) or the maternal artery (protocol 4), 15N label wasrecovered in the fetal vein, maternal vein and placental tissue as
15N-glutamine, 15N-aspartate, 15N-alanine, 15N-proline, 15N-leucine,
15N-valine and 15N-isoleucine (Supplemental data Figs. S1 and S2).
Production of 15N amino acids frommaternal or fetal 15N-glutamate
reached steady state at 3 h and remained essentially constant to 5 h
(Supplemental data Fig. S3). This data is not available for the 13C-
glutamate experiment.
Fig. 3. 13C-Glutamate disposal in the isolated perfused placenta perfused with 678 nmol/min (100 mmol/L) 98% 13CeU-glutamate for 300 min. 13C-Glutamine production was the
major route of glutamate disposal. For simplicity these estimates are based on Mþ5 glutamate and glutamine rather than including all isotopomers.
P.E.L. Day et al. / Placenta 34 (2013) 1223e123112283.6. Immuno-localisation of SNAT5 in placental syncytiotrophoblast
plasma membranes
rtPCR analysis demonstrated placental expression of SNAT3
(SLC38A3) and SNAT5 (SLC38A5) mRNA which was conﬁrmed by
sequencing of the PCR product (data not shown). SNAT5 was
immuno-localised to the maternal facing microvillous membrane
but not fetal facing basal membrane of the placental syncytio-
trophoblast (Fig. 4).3.7. 13C from glutamate was not incorporated into the lipid pool
Lipid incorporation of 13C-acetyl-CoA derived from 13C-gluta-
matewould be expected to generate mass isotopomer distributions
with increased relative intensities of Mþ1 and Mþ2 ion peaks.
Supplementary Fig. 3 shows that for selected lipid species exclu-
sively containing palmitate, the end product of fatty acid synthesis,
mass isotopomer distributions were identical before and after
perfusion (Fig. 5). More detailed calculation of M0:Mþ1 peak in-
tensities for all detected species of PC, PE, PS, PI, CE and DAGFig. 4. Western blot demonstrating localisation of the SNAT5 (SLC38A5), which can
mediate glutamine efﬂux, to the maternal facing microvillous membrane of placental
syncytiotrophoblast. There was no apparent SNAT5 localisation in the fetal facing basal
membrane.similarly found no increased relative Mþ1 ion intensities after 13C-
glutamate for any lipid species. These results suggest that under
these experimental conditions there was negligible conversion of
13C-glutamate to any of these lipids.
3.8. Estimated whole placental glutamine release into the maternal
circulation
After 5 h perfusion in a quasi-isotopic and metabolic steady
state, glutamine was released into the maternal circulation at a rate
of 140 nmol/min of 49% enriched glutamine from an average 27.5 g
cotyledon. Assuming an average placental weight of 470 g, and that
in vivo glutamine release occurs at a similar rate as the perfused
cotyledon then placental glutamine release into the maternal cir-
culation would equate to 7.0 mmol/day.
4. Discussion
This study demonstrates that the isolated perfused human
placenta can synthesise glutamine and that it can do so in biolog-
ically relevant amounts. An unexpected ﬁnding was that most of
this glutamine is transferred to the maternal rather than the fetal
circulation. We suggest that high rates of placental glutamine
production ensure that there is always sufﬁcient glutamine to meet
fetal requirements for growth and metabolism. In addition, pla-
centally derived glutaminemay playmetabolic and regulatory roles
within the placenta.
In the isolated perfused placenta net uptake of glutamate was
observed from both the maternal and fetal circulations indicating a
large placental metabolic demand. These observations are consis-
tent with the umbilical VeA difference for glutamate [20]. While
this glutamate was disposed of into a number of different pools, the
Fig. 5. Placental glutamine synthesis may drive uptake of amino acids for transport to the fetus. Glutamine is a substrate of 5 exchangers whose activity have been clearly
demonstrated in the placenta and is the only substrate transported by all these amino acid exchangers. System N (SNAT5) can mediate both uptake and efﬂux of glutamine
depending on the glutamine and Hþ ion gradients. For simplicity only selected transporters are shown on the MVM and BM.
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the ammonia required for glutamine production was derived from
the same metabolic pool, then an equivalent amount of 13C-gluta-
mate is likely to have been converted to a-ketoglutarate and
ammonia; in which case the glutamate used for the carbon back-
bone and for the provision of nitrogen for glutamine production
would account for around 90% of glutamate uptake by the isolated
perfused placental cotyledon. The appearance of 13C-aspartate as
well as Mþ1e4 isotopomers of glutamate and glutamine demon-
strates that this a-ketoglutarate is entering the Kreb’s cyclewhere it
will produce intermediarymetabolites and energy. Incorporation of
13C from glutamate was also observed in the proline pool and may
also be entering the placental protein pool, and together these
pathways may account for around 10% of glutamate disposal.
However, as the largest proportion of the 13C-glutamate is going to
glutamine and to a-ketoglutarate the underlying driver for
placental uptake and metabolism of glutamate is likely to be to
produce one or both of these compounds.
It should be noted that these experiments were undertaken in
the absence of physiological plasma concentrations of amino acids.
As substrate concentrations may directly and indirectly affect the
activity of metabolic pathways we cannot assume that our results
will be quantitatively similar to those obtained in vivo.
13C-Glutamine release from the perfused placenta was 7 mmol/
day which we estimate to be around 2% of maternal glutamine ﬂux
[21] but around 80% of placental delivery of glutamine to the fetus
[22,23]. Even if glutamine synthesis in vivo was higher it is not
likely that this would impact greatly on maternal metabolism
however it is clearly signiﬁcant for the fetus. If so, the question
arises of why this placental to maternal ﬂux occurs? We suggest
that placental glutamine production may serve to ensure that there
is always glutamine available for transfer to the fetus or that
glutamine synthesis serves a different metabolic requirement.Data from sheep suggest that the fetus derives a signiﬁcant
proportion of its energy from amino acid catabolism [24]. This fetal
amino acid consumption may in part reﬂect the metabolic
requirement of rapidly growing cells for glutamine [1,2]. It is
possible that a greater proportion of placentally derived glutamine
is destined for the fetus in vivo but that the placenta requires a fetal
signal to initiate this transport which is missing in the perfused
placenta. Whether SNAT5 mediates glutamine uptake or efﬂux
depends on hydrogen ion gradients and in vivo this may change
depending on metabolic status [25].
Consumption of amino acids by the placenta and the fetus will
produce amino nitrogen, which must be dealt with to prevent the
accumulation of ammonia and glutamine transfer may be traf-
ﬁcking excess nitrogen to the mother. While the fetus can synthe-
sise urea, the placenta cannot, and production of glutamine may
trafﬁc excess placental nitrogen back to themother [24]. Asmuch of
the glutamate converted to glutamine will come from the fetus it is
possible that, in addition to fetal urea production, placental gluta-
mate uptake may remove excess fetal nitrogen.
Production of the intermediary metabolite a-ketoglutarate
could provide an energy substrate for the placenta or may meet a
speciﬁc metabolic requirement. It may be that glutamine synthesis
occurs as a result of a-ketoglutarate production in order to transfer
the ammonia to the mother. In rapidly growing cells a-ketogluta-
rate from glutamine is incorporated into lipid [2]. However, no
evidence for incorporation of 13C into the lipid pool was observed
here and we have no evidence that this is a major pathway in the
placenta. While this particular pathway was not apparent in the
placenta a-ketoglutarate may meet some other metabolic
requirement.
Another possibility is that glutamine produced within the
placenta may facilitate uptake of other amino acids by exchange.
Glutamine is a substrate for 5 key amino acid exchangers expressed
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[14,26] (Fig. 4). This is particularly interesting as glutamine efﬂux
by exchange has been shown to facilitate uptake of substrates
which activate the mTOR pathway [27]. Glutamate levels in
maternal and fetal plasma are indicative of metabolic processes and
glutamate uptake may provide a link between maternal and fetal
metabolic status and placental mTOR activation.
4.1. Tissue amino acids levels
The tissue amino acid levels in the 13C-glutamate group were
maintained compared to baseline however in the 15N-leucine
experiment amino acid levels were reduced. One explanation for
the difference between the 13C-glutamate and 15N-leuicine exper-
iments is that plasma leucine, but not glutamate, stimulates efﬂux
of intracellular amino acids from the syncytiotrophoblast by amino
acid exchange and that the leucine taken up by exchange does not
accumulate as it diffuses out of the placenta via the basal mem-
brane facilitated transporters [14].
4.2. Metabolic and transporter compartmentalisation within the
syncytiotrophoblast
The data indicate that there is compartmentalisation of both
transport and metabolism within the placenta and more specif-
ically in placental syncytiotrophoblast. 13C-Glutamine enrichment
within the placenta was 5% and if this was the same in all placental
cell types then the enrichment of 13C-glutamine released into the
maternal and fetal veins could not exceed 5%. As release of gluta-
mine in to thematernal circulation had a 13C enrichment of 49% this
indicates that at least one cellular or subcellular compartment
within the placenta has a 13C-glutamine enrichment 49%. Other
cells or compartments must have a 13C-enrichment <5% such that
the average of the49% and<5% enriched compartments is 5% 13C-
glutamine. Similar evidence of metabolic compartmentalisation
within the placenta can be observed in the 15N-leucine and 15N-
glutamate experiments where tissue enrichment of speciﬁc amino
acids is lower than that released into fetal plasma.
The only placental cell type in direct contact with the maternal
circulation is the syncytiotrophoblast. For this reason the obser-
vation that the enrichment of glutamine secreted into the maternal
circulation was signiﬁcantly higher than into the fetal circulation
suggests that it was derived from the syncytiotrophoblast. If this
13C-glutamine were not made within the syncytiotrophoblast then
it would need to be transported through the syncytiotrophoblast to
reach the maternal circulation without becoming diluted by
endogenous 12C-glutamine within the syncytiotrophoblast. It is not
clear howenriched 13C-glutmaine from another cell type could pass
through the syncytiotrophoblast to reach the maternal circulation
while still having a signiﬁcantly greater enrichment than that
reaching the fetal circulation. For this reason we argue that the
synthesis of glutamine from glutamate within the placenta is pri-
marily occurring in the syncytiotrophoblast.
Our observation that SNAT5, a transporter capable of mediating
glutamine efﬂux, is localised to the maternal facing MVM is
consistent with the suggestion that the syncytiotrophoblast is the
most highly enriched compartment within the placenta.
To explain our observations the low enrichment compartments
would need to contain 4e9 fold as much amino acid as the highly
enriched compartment in order to dilute the 50% enriched 13C-
glutamine within the highly enriched compartment to an overall
tissue 5% enrichment. Given the relatively small volume of the
other placental cellular compartments (primarily endothelial cells
and cytotrophoblast) we suggest the syncytiotrophoblast itself
must be functionally compartmentalised [28,29]. Accumulation ofglycogen in ﬁrst trimester villi closest to the openings of uterine
glands provides an example of compartmentalisation within the
villi [30].
Further evidence of compartmentalisation may come from the
observation that 13C from glutamate did not appear in the alanine
pool. This was despite the fact that the appearance of Mþ3 aspar-
tate suggests that 13C-pyruvate is being produced and recycled into
the Kreb’s cycle and that 15N-alanine was produced by trans-
amination of pyruvate in the 15N experiments [31].
Exchange of 15N by aminotransferases observed within the
amino acid pool was limited to aspartate, alanine and the branched
chain amino acids. Serine and glycine can both be formed by
transamination via the alanine-glyoxylate (serine-pyruvate)
aminotransferase but consistent with our previous ﬁndings there
was no evidence for the transfer of 15N to these amino acids [32,33].
The relatively low tissue amino acid enrichments observed at
the end of the glutamate and leucine experiments suggests that the
free amino acid pool is being diluted by unlabelled amino acids.
This may reﬂect turnover of the protein pool, with protein break-
down releasing unlabelled amino acids into the free amino acid
pool and protein synthesis removing labelled and unlabelled amino
acids from this pool. The effect of protein turnover on the placental
amino acid pool deserves more attention, in particular because it
may have the capacity to buffer fetal amino acid supply in the event
of reduced maternal delivery.4.3. Conclusion
The isolated perfused human placenta has a signiﬁcant capacity
for glutamine synthesis and the substantive transfer of glutamine
to the mother suggests that placental synthesis may routinely
exceed fetal requirements. This may ensure that there is always
sufﬁcient glutamine to meet fetal requirements for growth. In
addition, placental synthesis may provide glutamine for other roles
including mediating the transfer of other amino acids by exchange,
regulation of placental function via mTOR and trafﬁcking of nitro-
gen to the mother. Placental glutamine metabolism provides
further evidence that the placenta is not a passive conduit for
maternal nutrients and future research needs to address whether
altered placental amino acid metabolism is a cause of fetal growth
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